Abstract 1949P
Background
Conventional use of doxorubicin as a single-agent or in combinations with other drugs in the treatment of uterine sarcomas is associated with dose-limiting toxicities. Doxorubicin plus trabectedin was shown to increase progression-free survival (PFS) at the price of higher toxicity. PLD plus trabectedin revealed to be feasible in larger phase 2 and 3 randomised studies in ovarian cancer. We hypothesise that the therapeutic index of trabectedin plus PLD could be superior to the combination with doxorubicin because of a more favourable toxicity profile.
Methods
In this retrospective single-arm study the clinical outcome was analysed in 21 patients with uterine sarcomas treated with PLD 30 mg/m2 plus trabectedin 1.1 mg/m2 every three weeks between January 2000 and April 2023 at the University Hospital in Innsbruck. Response evaluation was done every 3 cycles and every 3 months during the post-treatment follow-up. Toxicity was evaluated according to the National Cancer Institute-Common Terminology criteria, on a total of 148 administered cycles in 33 patients.
Results
In 66% of patients PLD plus trabectedin was given as first-line treatment, in 19% and 14% as second and third-line treatment, respectively. After 6 months one patient (4.8%) achieved complete remission (CR), four others (19%) showed a partial remission (PR), resulting in an objective response rate (ORR) of 24%. Four patients (19%) showing stable disease (SD), resulting in a clinical benefit rate (= ORR + SD) of 43%; progression was recorded in 12 patients (57%). Median PFS was 6.0 months (SD: ±21 months), while median overall survival was 26 months (SD: ±32 months). A median of 4 (range: 1-11) cycles per patient were given. Regarding ≥ grade 3 toxicity, thrombocytopenia was recorded in 9%, anaemia in 12% and neutropenia in 36% of patients. Febrile neutropenia was present in 7 patients (21%). Haematologic toxicity was the most frequent reason for dose delays (25 events) and dose reductions in eight cases.
Conclusions
Compared to conventional doxorubicin plus trabectedin, the herein investigated combination shows limited but similar anti-tumor efficacy in metastatic uterine sarcomas, but exhibits a more favourable toxicity profile.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1971P - Metastatic osteosarcoma, patterns of care and outcomes of patients in a real-life setting: The Metabone national observational study
Presenter: Mathilde Reich
Session: Poster session 15
1972P - Molecular mechanism study of recurrence/metastasis for Enneking IIb osteosarcoma
Presenter: Junqiang Yin
Session: Poster session 15
1975P - Systemic therapy for KIT/PDGFRA wild-type GIST
Presenter: Mehdi Brahmi
Session: Poster session 15
1976P - Financial difficulties experienced by gastrointestinal stromal tumor (GIST) patients in the Netherlands: Data from a cross-sectional multicenter study
Presenter: Deborah van de Wal
Session: Poster session 15
1977P - A registry-based analysis of the projected genomic landscape among unclassified KIT/PDGFRA wildtype mutations in patients with gastrointestinal stromal tumors
Presenter: Jerry Call
Session: Poster session 15
1978P - Identification of SDH-deficient GIST increases after the implementation of diagnostic algorithm in Life Raft Group (LRG) patient registry data
Presenter: Denisse Evans
Session: Poster session 15
1979P - phase I trial of pembrolizumab in HIV-associated Kaposi sarcoma (KS)
Presenter: Kathryn Lurain
Session: Poster session 15
1980P - Artificial intelligence analysis shows enhanced CCNG1 expression in sarcoma tumors, a novel biomarker for DeltaRex-G tumor targeted retrovector encoding a CCNG1 inhibitor gene
Presenter: Sant Chawla
Session: Poster session 15
1981P - Histopathological diagnostic discrepancies in bone and soft tissue tumors referred to a specialist sarcoma center and its clinical impact
Presenter: Akira Kawai
Session: Poster session 15